The Aporia
The Aporia
Shen, X. (2026, September 18). How China plans to ‘firmly rank at the global forefront’ with 25% of first-in-class drugs. South China Morning Post. https://www.scmp.com/business/china-business/article/3367952/how-china-plans-firmly-rank-global-forefront-25-first-class-drugs?utm_source=rss_feed
Shen, Xinmei. “How China plans to ‘firmly rank at the global forefront’ with 25% of first-in-class drugs.” South China Morning Post, 18 Sept. 2026, https://www.scmp.com/business/china-business/article/3367952/how-china-plans-firmly-rank-global-forefront-25-first-class-drugs?utm_source=rss_feed.
Shen, Xinmei. “How China plans to ‘firmly rank at the global forefront’ with 25% of first-in-class drugs.” South China Morning Post, September 18, 2026. https://www.scmp.com/business/china-business/article/3367952/how-china-plans-firmly-rank-global-forefront-25-first-class-drugs?utm_source=rss_feed.
Dated when The Aporia collected the article, usually within hours of publication. Check the original for its exact date and byline.
China aims to become a global biomedicine leader by 2030, targeting key technological advancements and capturing at least 25% of the world's first-in-class drugs market under its new five-year plan. The plan includes specific goals such as large pharmaceutical companies generating a combined revenue of no less than 3.5 trillion yuan (US$522 billion), and fostering at least 50 drug makers with annual revenues exceeding 10 billion yuan each. Sinopharm, the nation’s largest drug distributor, reported revenues of 575 billion yuan last year, indicating substantial growth potential in the sector.
